Regeneron Pharmaceuticals Inc (REGN)

Working capital turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	14,185,900	13,812,700	13,436,900	13,029,000	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900
Total current assets	US$ in thousands	18,660,900	19,333,600	19,081,600	18,871,500	19,479,200	18,634,800	16,923,000	16,909,200	15,884,100	15,428,600	15,529,900	14,306,000	14,014,900	13,775,400	13,337,600	10,055,100	9,779,100	9,097,600	7,860,200	8,644,100
Total current liabilities	US$ in thousands	3,944,300	3,661,000	3,508,600	3,580,900	3,423,400	3,598,600	3,104,400	3,100,100	3,141,300	2,879,200	3,033,900	3,007,600	3,932,500	3,714,800	3,732,400	3,217,800	2,697,400	2,337,800	3,702,400	2,055,200
Working capital turnover		0.96	0.88	0.86	0.85	0.81	0.87	0.91	0.89	0.95	1.09	1.13	1.46	1.59	1.34	1.28	1.34	1.19	1.21	1.92	1.21

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $14,185,900K ÷ ($18,660,900K – $3,944,300K)
= 0.96

Regeneron Pharmaceuticals Inc's working capital turnover ratio has fluctuated over the analyzed period. The ratio indicates how efficiently the company is utilizing its working capital to generate sales revenue. A higher ratio typically suggests more efficient management of working capital.

Based on the data provided:
- The working capital turnover ratio ranged from a low of 0.81 on December 31, 2023, to a high of 1.92 on June 30, 2020.
- Overall, the trend shows some variability, with the ratio generally decreasing from around mid-2022 onwards.
- The most recent data point, as of December 31, 2024, shows a working capital turnover ratio of 0.96, indicating a slight improvement from the previous quarter.

It is important for Regeneron Pharmaceuticals Inc to closely monitor this ratio as it reflects the company's efficiency in managing its working capital to support its operations. A consistent or increasing trend in the working capital turnover ratio would be favorable, as it signals effective utilization of resources to drive sales growth.